SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cavalry who wrote (330)9/21/1998 8:42:00 AM
From: Bleeker  Read Replies (2) of 857
 
Except 97,500 shares at $7 a pop buys a lot of food. HEB has traded
as low as 11.2 DM in Germany. At a conversion rate of 1.69 that's
about $6 5/8.

I agree that trailing earnings are not terribly important. I just
use it to get a sense if the valuation is excessive in connection
with other variables. My sense is forward earnings expectations
for the company are also too high, especially because of the
huge dilution; it's also very difficult to gauge market acceptance
for an FDA approved drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News